Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPO | P22079 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829172 | 0.97 | LPO (0.46) | LPOALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL8089847 | 0.77 | LPO (0.41) | LPOALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL8089840 | 0.77 | LPO (0.41) | LPOALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL8084747 | 0.77 | LPO (0.41) | LPOALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL5722623 | 0.77 | LPO (0.41) | LPOALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL8076693 | 0.73 | LPO (0.43) | LPOALDH1A1HSD17B10KMT2AKDM4E | |
| SCHEMBL5093089 | 0.73 | LPO (0.43) | LPOALDH1A1KMT2AKDM4EHTT | |
| SCHEMBL27769632 | 0.73 | LPO (0.43) | LPOKMT2AKDM4EHTTFDPS | |
| SCHEMBL8076701 | 0.72 | LPO (0.38) | LPOKDM4EHTTFDPSBRD4 | |
| SCHEMBL8088201 | 0.71 | LPO (0.36) | LPOALDH1A1HSD17B10KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240203727-A1 | METHOD OF DEPOSITING SILICON-BASED MATERIAL AND PRECURSORS FOR THE SAME | ASM IP HOLDING B.V. (NL) | 2024-06-20 | — | — | US | disclosed |
| CN-118207515-A | Method for depositing silicon-based materials and precursors thereof | ASM IP私人控股有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-6951948-B2 | Method for synthesis of substituted azole libraries | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-6683191-B2 | PREPARING A AZOLE COMPOUND ON A SOLID SUPPORT RESIN, CLEAVING THE COMPOUND FROM THE SOLID SUPPORT RESIN BY NUCLEOPHILIC SUBSTITUTION TO FURTHER SUBSTITUTING BY ALKYLATION REACTION | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2004-01-27 | — | — | US | disclosed |
| US-20020077483-A1 | Method for synthesis of substituted azole libraries | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-06-20 | — | — | US | disclosed |
| US-20020042520-A1 | Method for synthesis of substituted azole libraries | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2001094317-A2 | METHOD FOR SYNTHESIS OF SUBSTITUTED AZOLE LIBRARIES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001094318-A2 | METHOD FOR SYNTHESIS OF SUBSTITUTED AZOLE LIBRARIES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| EP-1050536-A2 | 2-(Benz-)Imidazol-, 2-(Benz-)Oxazol- or 2-(Benz-)Thiazol-substituted Silanes | Wacker-Chemie GmbH (DE) | 2000-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077483-A1 | Method for synthesis of substituted azole libraries | CYP51A1, LSS, CYP2F1 | LPO 3948/4885ALDH1A1 711/4885HPGD 1787/4885 |
| US-20020042520-A1 | Method for synthesis of substituted azole libraries | CYP51A1, LSS, CYP2F1 | LPO 3948/4885ALDH1A1 711/4885HPGD 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.